Sacituzumab govitecan (solution)
This product is an antibody–drug conjugate (ADC) targeting Trop-2, formulated here as a ready-to-use solution. It specifically combines a humanized anti-Trop-2 monoclonal antibody with SN-38, the active metabolite of irinotecan, to deliver targeted chemotherapy.
Key Features and Benefits
-
Trop-2 Targeting: Binds Trop-2, overexpressed in many epithelial cancers.
-
SN-38 Payload: Provides potent topoisomerase I inhibition.
-
ADC Design: Combines antibody targeting with cytotoxic drug delivery.
-
Solution Formulation: Offers convenience and immediate use.
-
High Purity: Ensures consistent quality for research or reference use.
Applications
-
Oncology Research: Supports studies on Trop-2–positive cancers.
-
Drug Development: Serves as a reference ADC for preclinical research.
-
Mechanistic Studies: Enables investigation of targeted topoisomerase inhibition.
-
Translational Research: Provides insights into ADC therapeutic strategies.
Storage and Handling
-
Storage: Store at –20 °C in a sealed, light-protected container.
-
Handling: Thaw carefully at room temperature; avoid repeated freeze–thaw cycles.
This product integrates Trop-2 targeting with SN-38 cytotoxicity, specifically offering a powerful ADC for cancer research and drug development.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
